FMWA
Forvis Mazars Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.71M | Sell |
3,252
-142
| -4% | -$74.6K | 0.04% | 168 |
|
|
2025
Q1 | $2.15M | Buy |
3,394
+139
| +4% | +$88.2K | 0.05% | 145 |
|
|
2024
Q4 | $2.32M | Buy |
3,255
+41
| +1% | +$29.2K | 0.05% | 150 |
|
|
2024
Q3 | $3.38M | Sell |
3,214
-49
| -2% | -$51.5K | 0.08% | 122 |
|
|
2024
Q2 | $3.43M | Buy |
3,263
+18
| +0.6% | +$18.9K | 0.09% | 118 |
|
|
2024
Q1 | $3.12M | Sell |
3,245
-43
| -1% | -$41.4K | 0.08% | 122 |
|
|
2023
Q4 | $2.89M | Sell |
3,288
-161
| -5% | -$141K | 0.08% | 124 |
|
|
2023
Q3 | $2.84M | Sell |
3,449
-1,574
| -31% | -$1.3M | 0.09% | 122 |
|
|
2023
Q2 | $3.61M | Buy |
5,023
+1,386
| +38% | +$996K | 0.11% | 119 |
|
|
2023
Q1 | $2.99M | Buy |
3,637
+91
| +3% | +$74.8K | 0.1% | 118 |
|
|
2022
Q4 | $2.56M | Buy |
3,546
+21
| +0.6% | +$15.2K | 0.09% | 126 |
|
|
2022
Q3 | $2.43M | Buy |
3,525
+174
| +5% | +$120K | 0.1% | 123 |
|
|
2022
Q2 | $1.98M | Buy |
3,351
+226
| +7% | +$134K | 0.08% | 126 |
|
|
2022
Q1 | $2.18M | Buy |
3,125
+365
| +13% | +$255K | 0.09% | 101 |
|
|
2021
Q4 | $1.74M | Buy |
2,760
+438
| +19% | +$277K | 0.07% | 112 |
|
|
2021
Q3 | $1.41M | Buy |
2,322
+1,738
| +298% | +$1.05M | 0.06% | 121 |
|
|
2021
Q2 | $326K | Buy |
+584
| New | +$326K | 0.02% | 213 |
|
|
2020
Q3 | – | Sell |
-441
| Closed | -$275K | – | 331 |
|
|
2020
Q2 | $275K | Sell |
441
-556
| -56% | -$347K | 0.02% | 258 |
|
|
2020
Q1 | $487K | Buy |
+997
| New | +$487K | 0.04% | 171 |
|